AMENDMENT NO. 2 TO DCADefinitive Collaboration Agreement • May 8th, 2023 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 2 (this “Second Amendment”) to that certain Definitive Collaboration Agreement dated as of June 9, 2020, as amended on May 27, 2022 (the “DCA”) is entered into as of February 8, 2023 and effective as of March 31, 2022 (“Second Amendment Effective Date”) by and among Glaxo Wellcome UK Limited, a private company limited by shares organized under the laws of England having an office at 980 Great West Road, Brentford, Middlesex TW8 9GS, England, registered under company number 00480080 (“GW”); and GlaxoSmithKline Biologicals S.A., a private company limited by shares organized under the laws of Belgium having its registered place of business at Rue de l’Institut 89 Rixensart, 1330 Belgium, as assignee of the DCA from Beecham S.A. (“GSK Bio”, together with GW, “GSK”), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). Capitalized terms used but not otherwise defined in this Second Amendme
AMENDMENT NO. 3 TO DCADefinitive Collaboration Agreement • May 8th, 2023 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 3 (this “Third Amendment”) to that certain Definitive Collaboration Agreement dated as of June 9, 2020, as amended on May 27, 2022 and February 8, 2023 (the “DCA”), is made and entered into as of February 8, 2023 (“Third Amendment Effective Date”) by and among Glaxo Wellcome UK Limited, a private company limited by shares organized under the laws of England having an office at 980 Great West Road, Brentford, Middlesex TW8 9GS, England, registered under company number 00480080 (“GW”); and GlaxoSmithKline Biologicals S.A., a private company limited by shares organized under the laws of Belgium having its registered place of business at Rue de l’Institut 89 Rixensart, 1330 Belgium, as assignee of the DCA from Beecham S.A. (“GSK Bio”, together with GW, “GSK”), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”). Capitalized terms used but not otherwise defined in this Third Amendment shal
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. VIA ELECTRONIC MAILAnd Invention Assignment Agreement • May 8th, 2023 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • California
On behalf of Vir Biotechnology, Inc. (“VirBio” or the “Company”), I am pleased to offer you employment with the Company in the position of Chief Executive Officer. This letter agreement (the “Agreement”) sets forth the terms and conditions of your employment with VirBio, should you accept our offer.
